Cambra was previously a vice president at Zimmer Biomet (NYSE:ZBH), “leading product management for their $5 billion global reconstruction business,” SpinaFX said in a news release. He served in that role from November 2020 to June 2021, according to his LinkedIn page.
He ended a nearly 11-year career at Medtronic (NYSE:MDT) in 2020, ultimately serving as vice president and general manager of interventional therapies. SpinaFX said he “led a successful turnaround of their $400 million vertebral augmentation and oncology business through new technology innovation, strategic partnerships, acquisitions and expanding margins.”
“With my passion for the interventional space, I constantly assess and monitor multiple promising technologies, I recognized the breakthrough potential of SpinaFX’s technology over a decade ago,” Camber said in the news release. “SpinaFX is an excellent opportunity to leverage my experience in the medical device field to deliver value for our patients, our customers and our shareholders.”
SpinaFX is headquartered near Toronto, Canada. The company said it has developed a minimally invasive, image-guided treatment for back pain from herniated discs, injecting a controlled oxygen formulation to reduce herniation and inflammation.
SpinaFX said its Triojection product was previously CE marked under the European Union’s Medical Device Directive and is undergoing recertification under the new Medical Device Regulation. Triojection is not yet approved for sale in North America, the U.K. or the EU.
“Jeff is a highly regarded leader in the medical device industry, with a proven track record of building great businesses and creating shareholder value,” SpinaFx Executive Chairman Igor Keselman said in the news release. “We’re confident that Jeff’s vision, operational discipline and commercial acumen make him the ideal leader for SpinaFX, and we’re excited to leverage his experience to help us reach the next level.”